{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T07:59:50Z","timestamp":1779350390918,"version":"3.51.4"},"reference-count":34,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Acute Myeloid Leukemia (AML) accounts for 20\u201325% of all leukemia diagnosed worldwide. According to Globoccan 2020, leukemia ranked the 15<jats:sup>th<\/jats:sup> most prevalent cancer with an estimated 474,519 new cases and 311,594 deaths annually. However, due to scarcity of well documented cancer registries, epidemiological and survival data of patients with AML is lacking in many African countries, including Tanzania. Therefore, the primary objective of this study was to determine the clinical features, laboratory characteristics and survival outcomes of AML patients treated with different regimens in Tanzania.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>Data from all adult patients diagnosed with AML at Muhimbili National Hospital (MNH) between January 2018 and December 2023 were analyzed in this retrospective study. STATA version 16 was used for data analysis. The survival outcome was calculated using the Kaplan-Meier method. To evaluate the statistical significance of the results, a p-value cut-off of 0.05 was used. The Cox proportional hazards model was used to identify predictors of survival and to estimate the effect of covariates on the hazard of death. Kruskal Wallis was used to compare the median values for laboratory results and pairwise comparison of median laboratory values was done using the Dunn Test.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 245 patients were diagnosed with acute leukemia during the five-year period (2018\u22122023), of which 169 (68%) had AML. The mean age at diagnosis was 47.2 (SD\u2009\u00b1\u200918.5) years. Majority of the patients were females (60.7%), and had de novo AML. Most of the patients presented with symptoms of anemia (98.2%) and fever (79.5%). The median survival time was 81 days with a one-year overall survival probability of 15.2%. Patients that resided outside of the Dar es Salaam region had a 74% increase hazard of mortality compared to those living within the Dar es Salaam region (aHR: 1.74, 95% CI: 1.15\u20132.64, p\u2009=\u20090.008). Patients receiving any form of chemotherapy had a 39% lower hazard of mortality compared to those who were on supportive treatment alone (aHR: 0.61, 95% CI: 0.40\u20130.93, p\u2009=\u20090.022).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>AML is the most common acute leukemia among adults in Tanzania, primarily affecting young females under 50 years. Resource constraints and limited treatment options result in poor outcomes, with a median survival of 81 days and one-year overall survival of 15.2%.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0332237","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T21:00:53Z","timestamp":1758315653000},"page":"e0332237","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Low survival in younger adults with Acute Myeloid Leukemia (AML) in Tanzania linked to high disease burden and socioeconomic factors"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9597-2922","authenticated-orcid":true,"given":"Michelle","family":"Munroe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5154-7872","authenticated-orcid":true,"given":"Clara","family":"Chamba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0764-0196","authenticated-orcid":true,"given":"Mbonea","family":"Yonazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samira","family":"Mahfudh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Mawalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0717-1791","authenticated-orcid":true,"given":"Kelvin","family":"Mbelekwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gladys","family":"Kaaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebbecca","family":"Mwakichako","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johnson","family":"Mshiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Lyimo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mwashungi","family":"Ally","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahlam","family":"Nasser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"key":"pone.0332237.ref001","volume-title":"Acute Myeloid Leukemia","author":"AMP Vakiti","year":"2023"},{"key":"pone.0332237.ref002","unstructured":"Zelepis K. Leukemia UK: Acute Myeloid Leukemia. https:\/\/www.leukaemiauk.org.uk\/about-leukaemia\/types-of-leukaemia\/acute-myeloid-leukaemia-aml\/. 2020. 2023 July 1."},{"key":"pone.0332237.ref003","volume-title":"Cancer in sub-Saharan Africa, volume III","author":"Union for International Cancer Control","year":"2019"},{"issue":"10","key":"pone.0332237.ref004","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(21)00198-8","article-title":"Haematological malignancies in sub-Saharan Africa: east Africa as an example for improving care","volume":"8","author":"CD Okello","year":"2021","journal-title":"Lancet Haematol"},{"key":"pone.0332237.ref005","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1182\/blood-2021-153626","article-title":"Acute Myeloid Leukemia in Western Kenya: A Snapshot","volume":"138","author":"CM Wanjiku","year":"2021","journal-title":"Blood"},{"issue":"5","key":"pone.0332237.ref006","article-title":"Hematological malignancies in East Africa-Which cancers to expect and how to provide services","volume":"15","author":"SA Leak","year":"2020","journal-title":"PLoS One"},{"key":"pone.0332237.ref007","article-title":"One-Year Survival and Prognosticators of Adults With Acute Leukemia at the Uganda Cancer Institute","volume":"9","author":"B Natukunda","year":"2023","journal-title":"JCO Glob Oncol"},{"key":"pone.0332237.ref008","first-page":"1","article-title":"Pediatric Cancer in Northern Tanzania: Evaluation of Diagnosis, Treatment, and Outcomes","volume":"4","author":"K Schroeder","year":"2018","journal-title":"J Glob Oncol"},{"issue":"12","key":"pone.0332237.ref009","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1002\/pbc.24576","article-title":"Current treatment and outcome for childhood acute leukemia in Tanzania","volume":"60","author":"E Kersten","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"pone.0332237.ref010","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/ajh.26079","article-title":"Determination of fitness and therapeutic options in older patients with acute myeloid leukemia","volume":"96","author":"JE Cortes","year":"2021","journal-title":"Am J Hematol"},{"issue":"9","key":"pone.0332237.ref011","doi-asserted-by":"crossref","first-page":"6245","DOI":"10.3390\/curroncol29090491","article-title":"Management of Acute Myeloid Leukemia: A Review for General Practitioners in Oncology","volume":"29","author":"RJ Stubbins","year":"2022","journal-title":"Curr Oncol"},{"issue":"10","key":"pone.0332237.ref012","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1097\/MS9.0000000000001189","article-title":"Prevalence of acute myeloid leukemia and its associated risk factors at a tertiary care center: a retrospective cross-sectional study","volume":"85","author":"PS Chaurasiya","year":"2023","journal-title":"Ann Med Surg (Lond)"},{"issue":"9","key":"pone.0332237.ref013","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","article-title":"Age and acute myeloid leukemia","volume":"107","author":"FR Appelbaum","year":"2006","journal-title":"Blood"},{"issue":"7714","key":"pone.0332237.ref014","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s41586-018-0317-6","article-title":"Prediction of acute myeloid leukaemia risk in healthy individuals","volume":"559","author":"S Abelson","year":"2018","journal-title":"Nature"},{"issue":"12","key":"pone.0332237.ref015","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1007\/s00277-017-3150-3","article-title":"Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)","volume":"96","author":"G Nagel","year":"2017","journal-title":"Ann Hematol"},{"key":"pone.0332237.ref016","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges","volume":"36","author":"RM Shallis","year":"2019","journal-title":"Blood Rev"},{"issue":"1","key":"pone.0332237.ref017","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13045-020-00908-z","article-title":"The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017","volume":"13","author":"M Yi","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"1","key":"pone.0332237.ref018","doi-asserted-by":"crossref","DOI":"10.4084\/MJHID.2022.013","article-title":"Clinical and prognostic features in a young adult patient with de novo myelodysplastic syndrome presenting t(11;16)(q23;q24)","volume":"14","author":"V Lamim Lovatel","year":"2022","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"1","key":"pone.0332237.ref019","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1182\/blood.2019000942","article-title":"Genetics of progression from MDS to secondary leukemia","volume":"136","author":"AJ Menssen","year":"2020","journal-title":"Blood"},{"key":"pone.0332237.ref020","doi-asserted-by":"crossref","first-page":"106857","DOI":"10.1016\/j.leukres.2022.106857","article-title":"De Novo myelodysplastic syndromes in patients 20-50 years old are enriched for adverse risk features","volume":"117","author":"ZD Epstein-Peterson","year":"2022","journal-title":"Leuk Res"},{"issue":"1","key":"pone.0332237.ref021","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood-2011-04-347872","article-title":"Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007","volume":"119","author":"GM Dores","year":"2012","journal-title":"Blood"},{"issue":"12","key":"pone.0332237.ref022","first-page":"875","article-title":"The leukaemia research fund data collection survey: the incidence and geographical distribution of acute myeloid leukemia","volume":"3","author":"PA McKinney","year":"1989","journal-title":"Leukemia"},{"key":"pone.0332237.ref023","unstructured":"Stocks N. Tanzania: Total population from 2012 to 2022, by gender. https:\/\/www.statista.com\/statistics\/967937\/total-population-of-tanzania-by-gender\/. 2016. 2024 June 13."},{"key":"pone.0332237.ref024","volume-title":"Hematology in Practice","author":"B. Cisella","year":"2012","edition":"2"},{"issue":"2","key":"pone.0332237.ref025","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40487-016-0029-8","article-title":"The Patient Perspective on Living with Acute Myeloid Leukemia","volume":"4","author":"EL Tomaszewski","year":"2016","journal-title":"Oncol Ther"},{"issue":"12","key":"pone.0332237.ref026","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41408-017-0011-1","article-title":"Improved outcome for AML patients over the years 2000-2014","volume":"7","author":"S Bertoli","year":"2017","journal-title":"Blood Cancer Journal"},{"issue":"4","key":"pone.0332237.ref027","doi-asserted-by":"crossref","first-page":"43","DOI":"10.46989\/001c.124273","article-title":"Determinants of Outcomes for Acute Myeloid Leukemia Patients Treated in a Community-Based Specialized Versus Non-Specialized Hospital Setting","volume":"6","author":"M Battiwalla","year":"2024","journal-title":"Clin Hematol Int"},{"issue":"3","key":"pone.0332237.ref028","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.clml.2019.12.007","article-title":"Treatment Strategies for Therapy-related Acute Myeloid Leukemia","volume":"20","author":"P Dhakal","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"pone.0332237.ref029","article-title":"Cancer Care in Resource-Limited Countries: Jordan as an Example","volume":"10","author":"H Abdel-Razeq","year":"2024","journal-title":"JCO Glob Oncol"},{"key":"pone.0332237.ref030","article-title":"Cancer in developing countries: challenges and solutions","author":"AV Reeler","year":"2006","journal-title":"Ann Oncol"},{"issue":"18","key":"pone.0332237.ref031","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1182\/blood-2013-01-476614","article-title":"Effectiveness of supportive care measures to reduce infections in pediatric AML: a report from the Children\u2019s Oncology Group","volume":"121","author":"L Sung","year":"2013","journal-title":"Blood"},{"issue":"1","key":"pone.0332237.ref032","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/hematology.2020000097","article-title":"Practice patterns and outcomes for adults with acute myeloid leukemia receiving care in community vs academic settings","volume":"2020","author":"AB Halpern","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"7","key":"pone.0332237.ref033","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1093\/annonc\/mdm112","article-title":"Positive impact of selective outpatient management of high-risk acute myelogenous leukemia on the incidence of septicemia","volume":"18","author":"TY Halim","year":"2007","journal-title":"Ann Oncol"},{"key":"pone.0332237.ref034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2024\/1937419","article-title":"Challenges and outcomes of the first stem cell transplant program in Tanzania, East Africa","volume":"2024","author":"S Rwezaula","year":"2024","journal-title":"Adv Hematol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0332237","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T21:53:16Z","timestamp":1758318796000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0332237"}},"subtitle":[],"editor":[{"given":"Daniel","family":"Thomas","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":34,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0332237","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,19]]}}}